CIK 0001540159
- Non-accelerated filer
- Smaller reporting company
Edesa Biotech, Inc.
Sign in to watch- Ticker
- EDSA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Sep 30
- Incorporated
- British Columbia, Canada
- Entity type
- Operating
- Phone
- +1 905-475-1234
- Business address
- C/O FASKEN MARTINEAU DUMOULIN LLP, 333 BAY STREET, SUITE 2400, TORONTO, Ontario, Canada, M5H 2T6
- Former names
- Stellar Biotechnologies, Inc.
- 4 Option exercise Director acquired 4,262 shares (option exercise)
- 4 Option exercise President acquired 914 shares (option exercise)
- 4 Option exercise Chief Financial Officer acquired 609 shares (option exercise)
- 4 Option exercise Director acquired 1,218 shares (option exercise)
- 4 Option exercise Chief Executive Officer acquired 4,628 shares (option exercise)
- 4 Option exercise Director acquired 609 shares (option exercise)
- 4 Option exercise Director acquired 70,314 shares (option exercise)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Other acquisition Chief Executive Officer acquired 371,727 shares (other)
- 4 Open-market buy President bought 2,500 shares at an average $3.00 ($7,499)
- 4 Open-market buy Chief Executive Officer bought 3,000 shares at $2.98 ($8,939)
- 4 Open-market buy Chief Executive Officer bought 5,000 shares at an average $1.87 ($9,373)
Page 8 of 14 · 261 filings